Abstract

BackgroundOvarian cancer greatly threatens the general health of women worldwide. Implementation of predictive prognostic biomarkers aids in ovarian cancer management.MethodsUsing online databases, the general expression profile, target-disease associations, and interaction network of PAWR were explored. To identify the role of PAWR in ovarian cancer, gene correlation analysis, survival analysis, and combined analysis of drug responsiveness and PAWR expression were performed. The predictive prognostic value of PAWR was further validated in clinical samples.ResultsPAWR was widely expressed in normal and cancer tissues, with decreased expression in ovarian cancer tissues compared with normal tissues. PAWR was associated with various cancers including ovarian cancer. PAWR formed a regulatory network with a group of proteins and correlated with several genes, which were both implicated in ovarian cancer and drug responsiveness. High PAWR expression denoted better survival in ovarian cancer patients (OS: HR = 0.84, P = 0.0077; PFS, HR = 0.86, P = 0.049). Expression of PAWR could predict platinum responsiveness in ovarian cancer and there was a positive correlation between PAWR gene effect and paclitaxel sensitivity. In 12 paired clinical samples, the cancerous tissues exhibited significantly lower PAWR expression than matched normal fallopian tubes. The predictive prognostic value of PAWR was maintained in a cohort of 50 ovarian cancer patients.ConclusionsHigh PAWR expression indicated better survival and higher drug responsiveness in ovarian cancer patients. PAWR could be exploited as a predictive prognostic biomarker in ovarian cancer.

Highlights

  • Ovarian cancer greatly threatens the general health of women worldwide

  • Regulatory network of PAWRBy exploring the Gene Resource of the National Center for Biotechnology Information, we identified 80 proteins that might interact with PRKC apoptosis WTI regulator (PAWR)

  • PAWR expression indicates drug responsiveness of ovarian cancer Since platinum agents constitute the standard of chemotherapy for ovarian cancer [1], we explored Dependency Map portal (DepMap) to identify the gene effect of PAWR on platinum responsiveness

Read more

Summary

Introduction

Ovarian cancer greatly threatens the general health of women worldwide. Implementation of predictive prognostic biomarkers aids in ovarian cancer management. Ovarian cancer ranks seventh the most common cancer, causing 152,000 deaths annually worldwide (4.3% of all cancer deaths), and the 5-year survival rate for ovarian cancer has remained unchanged for decades [1]. The introductions of platinum in 1976 and paclitaxel in 1993 have greatly improved the outcomes of ovarian cancer patients [1,2,3]. The majority of patients develop resistance and recurrence [1, 5]. Implementation of predictive prognostic biomarkers could facilitate the management of ovarian cancer [1, 4,5,6,7]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call